301258 logo

Suzhou Fushilai Pharmaceutical Co., Ltd. Stock Price

SZSE:301258 Community·CN¥3.1b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

301258 Share Price Performance

CN¥0
-24.49 (-100.00%)
CN¥0
-24.49 (-100.00%)
Price CN¥0

301258 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with acceptable track record.

2 Risks
2 Rewards

Suzhou Fushilai Pharmaceutical Co., Ltd. Key Details

CN¥439.6m

Revenue

CN¥365.5m

Cost of Revenue

CN¥74.1m

Gross Profit

-CN¥1.9m

Other Expenses

CN¥76.0m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Apr 23, 2026
0.85
16.85%
17.28%
0%
View Full Analysis

About 301258

Founded
2000
Employees
524
CEO
Xiangyun Qian
WebsiteView website
www.fuslai.com

Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; l-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonsteroidal anti-inflammatory analgesic used to relieve the pain symptoms of osteoarthritis. Its products are used in medicines, dietary supplements, and cosmetics applications. The company also engages in research and experimental development and capital market activities. The company exports its products to Europe, America, and Southeast Asia. Suzhou Fushilai Pharmaceutical Co., Ltd. was founded in 2000 and is based in Changshu, China.

Recent 301258 News & Updates

Recent updates

No updates